Metagenomi, Inc. (MGX): Balans kapitallashuviga qarzlar

Metagenomi (MGX) kompaniyasining korporativ logotipi

Metagenomi, Inc. (MGX) yirik biofarmatsevtika korporatsiyalari bilan hamkorlikda aniq genlarni tahrirlash vositalarini ishlab chiqadi. Bozor kapitalizatsiyasiga nisbatan leveraj koeffitsiyenti moliyaviy yukni aniq ko'rsatadi, bunda 0.34 ushbu parametrning darajasini belgilaydi. Kompaniya kuchli patent raqobati sharoitida DNK modifikatsiya tizimlarini aniqlash uchun AI texnologiyasidan foydalanadi. Ekologik iz minimal darajada bo'lib, standart laboratoriya nazoratlari bilan cheklangan.

Qarzning balans kapitaliga nisbati: Metagenomi Therapeutics (MGX) 21.02.2024 - 28.10.2026 uchun

Metagenomi Inc. (MGX) kompaniyasi koʻrsatkichlari kesimi va tahlili

- narx va narxlar bo'yicha konsensus prognoz:
Narx grafigi Metagenomi, Inc.|MGX - Konsensus maqsadli narx
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi Metagenomi Therapeutics|MGX - Korxonaning umumiy qiymati
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya uchun buxgalteriya qiymati Metagenomi|MGX - Jami sof aktivlar|Bozor kapitallashuvining balans qiymatiga nisbati metagenomi.co|MGX - Kompaniyaning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning kapitalga nisbati Metagenomi, Inc.|MGX - Uzoq muddatli qarzdorlikning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati Metagenomi, Inc|MGX - Kompaniyaning umumiy yig'indi qarzi|Qarzning balans kapitallashuviga nisbati Metagenomi Therapeutics|MGX - Kompaniyaning uzoq muddatli qarzdorligi|Kompaniyaning qisqa muddatli qarzi Metagenomi
Kompaniyaning jamlanma tahliliyoti:MGX - Metagenomi, Inc.
Metagenomi Inc. tayyor mahsulotlari

Ushbu ko'rsatkich balans hisobotidagi umumiy majburiyatlarning kompaniya umumiy kapitaliga nisbatini belgilaydi. Kitob kapitalizatsiyasida qarz moliyalashtirish ulushini tahlil qilish orqali investor moliyaviy richagning darajasini va defolt xavfini baholaydi. Mazkur metrika majburiyatlar tuzilmasidagi o'zgarishlarga va jalb qilingan mablag'lar hajmiga sezgir hisoblanadi. Metagenomi, Inc. (MGX) uchun past richag darajasi juda muhimdir, chunki u patentlangan texnologiyalarning tijoratlashtirilishi va klinikadan oldingi tadqiqotlar yakunlanishigacha moliyaviy barqarorlikni ta'minlaydi.

Metagenomi, Inc. kimlar bilan raqobatlashadi

Tempus AI Inc - Qarzning balans kapitallashuviga nisbati|Qarzning balans qiymatiga nisbati qiagen.com QGEN|IONS (Ionis) - Balans kapitallashuviga qarzlar|Repligen Corp (RGEN) - Balans qiymatiga qarzlar|RNA - Qarzning balans qiymatiga nisbati|CRISPR (CRSP) - Qarzning balans kapitaliga nisbati|WGS (GeneDx Holdings Corp.) - Balans kapitallashuviga qarzlar|Balans kapitallashuviga qarzlar ultragenyx.com|BEAM: Balans kapitallashuviga qarzlar|Qarzning sof aktivlarga nisbati Sarepta Therapeutics (SRPT)|TWST: Balans kapitallashuviga qarzlar|10x - Balans qiymatiga qarzlar|Intellia Therapeutics (NTLA) - Qarzning balans kapitallashuviga nisbati|STOK: Qarzning balans qiymatiga nisbati|Qarzning balans kapitallashuviga nisbati BLFS|WVE (Wave Life Sciences Ltd) - Balans qiymatiga qarzlar|Qarzning balans kapitallashuviga nisbati MAZE|Qarzning balans qiymatiga nisbati Sionna Corp|PRME (Prime Medicine, Inc.) - Balans kapitallashuviga qarzlar|Sof aktivlarga qarzlar tayshagtx.com TSHA|Qarzning balans qiymatiga nisbati uniQure|Qarzning sof aktivlarga nisbati MeiraGTx Holdings MGTX|Balans kapitallashuviga qarzlar RGNX (Regenxbio)|SLDB: Sof aktivlarga qarzlar|Qarzning balans kapitallashuviga nisbati Ocugen, Inc.|pacb.com (PACB) - Qarzning balans qiymatiga nisbati|Balans kapitallashuviga qarzlar BNTC|Qarzning balans qiymatiga nisbati Design Therapeutics Inc (DSGN)|RCKT (Rocket Pharmaceuticals Inc) - Qarzning balans qiymatiga nisbati|Sof aktivlarga qarzlar FDMT (4D Molecular Corp)|Lexeo Therapeutics, Inc. - Qarzning balans kapitallashuviga nisbati|Qarzning balans qiymatiga nisbati Korro Bio Inc. KRRO|Balans kapitallashuviga qarzlar EDIT|Silence Therapeutics PLC (SLN) - Qarzning sof aktivlarga nisbati|Qarzning balans qiymatiga nisbati proqr.com|Codexis (CDXS) - Qarzning balans qiymatiga nisbati|Balans kapitallashuviga qarzlar Sangamo Therapeutics (SGMO)|Qarzning balans qiymatiga nisbati NAUT|Qarzning balans kapitallashuviga nisbati Precision BioSciences, Inc. DTIL|Qarzning balans qiymatiga nisbati generationbio.com (GBIO)|Balans kapitallashuviga qarzlar BOLD (Boundless Bio, Inc)|Exicure Inc. - Balans kapitallashuviga qarzlar|IMNN: Qarzning balans kapitallashuviga nisbati|PHIO - Qarzning balans qiymatiga nisbati|Balans kapitallashuviga qarzlar MBIO|Balans qiymatiga qarzlar TransCode Therapeutics, Inc.|Bionano Genomics Inc. (BNGO) - Qarzning balans qiymatiga nisbati|Qarzning balans kapitaliga nisbati Applied DNA Corp|Balans kapitallashuviga qarzlar BLUE|Balans kapitallashuviga qarzlar immunoprecise.com (IPA)|OMGA (Omega Therapeutics, Inc.) - Balans kapitallashuviga qarzlar|Qarzning sof aktivlarga nisbati Singular Genomics Systems, Inc. OMIC|RGLS (Regulus Therapeutics Inc) - Balans kapitallashuviga qarzlar|SYRS: Balans qiymatiga qarzlar|Qarzning balans kapitallashuviga nisbati Telesis Bio, Inc.|TCON (traconpharma.com) - Qarzning balans qiymatiga nisbati|Qarzning balans kapitallashuviga nisbati UBX (Unity Biotechnology, Inc.)